78 related articles for article (PubMed ID: 21492498)
1. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study.
Barak Y; Plopski I; Tadger S; Paleacu D
Int Psychogeriatr; 2011 Nov; 23(9):1515-9. PubMed ID: 21492498
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.
Ismail Z; Emeremni CA; Houck PR; Mazumdar S; Rosen J; Rajji TK; Pollock BG; Mulsant BH
Am J Geriatr Psychiatry; 2013 Jan; 21(1):78-87. PubMed ID: 23290205
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation.
Oguma T; Jino K
Chem Pharm Bull (Tokyo); 2024; 72(7):610-617. PubMed ID: 38945937
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Risperidone in Patients With Delirium: The RIDDLE Pilot Study.
Nguyen PV; Vu TTM
J Clin Psychopharmacol; 2024 Jan-Feb 01; 44(1):30-34. PubMed ID: 38011032
[TBL] [Abstract][Full Text] [Related]
5. Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation.
Lavretsky H
Am J Psychiatry; 2017 Apr; 174(4):307-308. PubMed ID: 28366091
[No Abstract] [Full Text] [Related]
6. Antipsychotics in Alzheimer's Disease: Current Status and Therapeutic Alternatives.
Maziero MP; Rocha NP; Teixeira AL
Curr Alzheimer Res; 2023; 20(10):682-691. PubMed ID: 38409713
[TBL] [Abstract][Full Text] [Related]
7. New-Onset Psychosis in the Context of COVID-19 Infection: An Illustrative Case and Literature Review.
O'Leary KB; Keenmon C
J Acad Consult Liaison Psychiatry; 2023; 64(4):383-391. PubMed ID: 36634910
[TBL] [Abstract][Full Text] [Related]
8. Combination of antidepressants and antipsychotics as a novel treatment option for psychosis in Alzheimer's disease.
Fan P; Zeng L; Ding Y; Kofler J; Silverstein J; Krivinko J; Sweet RA; Wang L
CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1119-1131. PubMed ID: 37128639
[TBL] [Abstract][Full Text] [Related]
9. Guiding safer risperidone prescribing in Alzheimer's disease with therapeutic drug monitoring.
Roughley M; Mena C; Howard R; Reeves S; Bertrand J
Br J Clin Pharmacol; 2023 Jul; 89(7):2316-2321. PubMed ID: 36791792
[TBL] [Abstract][Full Text] [Related]
10. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
[TBL] [Abstract][Full Text] [Related]
11. Citalopram for agitation in Alzheimer's disease: design and methods.
Drye LT; Ismail Z; Porsteinsson AP; Rosenberg PB; Weintraub D; Marano C; Pelton G; Frangakis C; Rabins PV; Munro CA; Meinert CL; Devanand DP; Yesavage J; Mintzer JE; Schneider LS; Pollock BG; Lyketsos CG;
Alzheimers Dement; 2012; 8(2):121-30. PubMed ID: 22301195
[TBL] [Abstract][Full Text] [Related]
12. Agitation and aggression in people with Alzheimer's disease.
Ballard C; Corbett A
Curr Opin Psychiatry; 2013 May; 26(3):252-9. PubMed ID: 23528917
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.
Seitz DP; Gill SS; Herrmann N; Brisbin S; Rapoport MJ; Rines J; Wilson K; Le Clair K; Conn DK
Int Psychogeriatr; 2013 Feb; 25(2):185-203. PubMed ID: 23083438
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.
Maust DT; Kim HM; Seyfried LS; Chiang C; Kavanagh J; Schneider LS; Kales HC
JAMA Psychiatry; 2015 May; 72(5):438-45. PubMed ID: 25786075
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial.
Bergh S; Selbæk G; Engedal K
BMJ; 2012 Mar; 344():e1566. PubMed ID: 22408266
[TBL] [Abstract][Full Text] [Related]
16. Role of citalopram in the treatment of agitation in Alzheimer's disease.
Porsteinsson AP; Keltz MA; Smith JS
Neurodegener Dis Manag; 2014; 4(5):345-9. PubMed ID: 25405648
[TBL] [Abstract][Full Text] [Related]
17. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
Freund-Levi Y; Bloniecki V; Auestad B; Tysen Bäckström AC; Lärksäter M; Aarsland D
Dement Geriatr Cogn Disord; 2014; 38(3-4):234-44. PubMed ID: 24969380
[TBL] [Abstract][Full Text] [Related]
18. Can antidepressant medication relieve agitation in Alzheimer's disease?
Porsteinsson AP; Smith JS; Keltz MA; Antonsdottir IM
Expert Rev Neurother; 2014 Sep; 14(9):969-71. PubMed ID: 25148535
[TBL] [Abstract][Full Text] [Related]
19. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
Herrmann N; Gauthier S; Boneva N; Lemming OM;
Int Psychogeriatr; 2013 Jun; 25(6):919-27. PubMed ID: 23472619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
